Abstract
The endocannabinoid, N-arachidonylethanolamine (AEA) is accumulated by neurons via a process that has been characterized biochemically but not molecularly. Inhibitors of AEA accumulation have been characterized individually but have not been compared in a single study. Our purpose was to compare the potency of five previously described compounds (AM404, AM1172, VDM11, OMDM-2, and UCM707) both as inhibitors of AEA and N-palmitoylethanolamine (PEA) accumulation by cerebellar granule neurons and as inhibitors of AEA hydrolysis. The compounds all inhibited AEA accumulation; AM404, VDM11 and OMDM-2 with IC50 values of approximately 5 μM, whereas AM1172 and UCM707 exhibited IC50 values of 24 and 30 μM, respectively. The compounds also inhibited PEA accumulation; AM404 being the most potent with an IC50 of 6 μM, whereas the other compounds had IC50 values in the range of 30–70 μM. All of the compounds potently inhibited AEA hydrolysis by brain membranes; the K I values for AM404, VDM11, and UCM707 were less than 1 μM; AM1172 and OMDM-2 exhibited K I values of 3 and 10 μM, respectively. The IC50 values for inhibition of AEA accumulation were compared to the IC50 values for PEA accumulation and AEA hydrolysis using linear regression. None of the regressions were significant. These data indicate that inhibition of AEA accumulation by neurons is not a result of the inhibition of endocannabinoid hydrolysis and is a process different from the accumulation of PEA. These studies support the hypothesis that the cellular AEA accumulation beyond simple equilibrium between intracellular and extracellular concentrations occurs because AEA binds to an intracellular protein that is not FAAH but that also recognizes the AEA uptake inhibitors.
Similar content being viewed by others
References
Beltramo, M., di Tomaso, E., & Piomelli, D. (1997a). Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one. Federation of European Biochemical Societies letters, 403, 263–267.
Beltramo, M., Stella, N., Calignano, A., Lin, S. Y., Makriyannis, A., & Piomelli, D. (1997b). Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science, 277, 1094–1097.
Day, T. A., Rakhshan, F., Deutsch, D. G., & Barker, E. L. (2001). Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Molecular Pharmacology, 59, 1369–1375.
De Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000). Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: Inhibitors of anandamide uptake with negligible capsaicin-like activity. Federation of European Biochemical Societies letters, 483, 52–56.
Fegley, D., Kathuria, S., Mercier, R., Li, C., Goutopoulos, A., Makriyannis, A., et al. (2004). Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proceedings of the National Academy of Sciences of the United States of America, 101, 8756–8761.
Fowler, C. J., Tiger, G., Ligresti, A., Lopez-Rodriguez, M. L., & Di Marzo, V. (2004). Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis—a difficult issue to handle. European Journal of Pharmacology, 492, 1–11.
Glaser, S. T., Abumrad, N. A., Fatade, F., Kaczocha, M., Studholme, K. M., & Deutsch, D. G. (2003). Evidence against the presence of an anandamide transporter. Proceedings of the National Academy of Sciences of the United States of America, 100, 4269–4274.
Hillard, C. J., & Jarrahian, A. (2003). Cellular accumulation of anandamide: Consensus and controversy. British Journal of Pharmacology, 140, 802–808.
Hillard, C. J., & Jarrahian, A. (2005). Accumulation of anandamide: Evidence for cellular diversity. Neuropharmacology, 48, 1072–1078.
Hillard, C. J., Wilkison, D. M., Edgemond, W. S., & Campbell, W. B. (1995). Characterization of the kinetics and distribution of N-arachidonylethanolamine (anandamide) hydrolysis by rat brain. Biochimica et Biophysica Acta, 1257, 249–256.
Hillard, C. J., Edgemond, W. S., Jarrahian, A., & Campbell, W. B. (1997). Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. Journal of Neurochemistry, 69, 631–638.
Jacobsson, S. O., & Fowler, C. J. (2001). Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: Comparison with anandamide. British Journal of Pharmacology, 132, 1743–1754.
Jarrahian, A., Manna, S., Edgemond, W. S., Campbell, W. B., & Hillard, C. J. (2000). Structure–activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter. Journal of Neurochemistry, 74, 2597–2606.
Lang, W., Qin, C., Lin, S., Khanolkar, A. D., Goutopoulos, A., Fan, P., et al. (1999). Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. Journal of Medicinal Chemistry, 42, 896–902.
Lopez-Rodriguez, M. L., Viso, A., Ortega-Gutierrez, S., Lastres-Becker, I., Gonzalez, S., Fernandez-Ruiz, J., et al. (2001). Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. Journal of Medicinal Chemistry, 44, 4505–4508.
Lopez-Rodriguez, M. L., Viso, A., Ortega-Gutierrez, S., Fowler, C. J., Tiger, G., de Lago, E., et al. (2003). Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase. Journal of Medicinal Chemistry, 46, 1512–1522.
Ortar, G., Ligresti, A., De Petrocellis, L., Morera, E., & Di Marzo, V. (2003). Novel selective and metabolically stable inhibitors of anandamide cellular uptake. Biochemical Pharmacology, 65, 1473–1481.
Ortega-Gutierrez, S., Hawkins, E. G., Viso, A., Lopez-Rodriguez, M. L., & Cravatt, B. F. (2004). Comparison of anandamide transport in FAAH wild-type and knockout neurons: Evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. Biochemistry, 43, 8184–8190.
Piomelli, D., Beltramo, M., Glasnapp, S., Lin, S. Y., Goutopoulos, A., Xie, X. Q., et al. (1999). Structural determinants for recognition and translocation by the anandamide transporter. Proceedings of the National Academy of Sciences, 96, 5802–5807.
Ruiz-Llorente, L., Ortega-Gutierrez, S., Viso, A., Sanchez, M. G., Sanchez, A. M., Fernandez, C., et al. (2004). Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: Synthesis of new transporter inhibitors as tools for this study. British Journal of Pharmacology, 141, 457–467.
Vandevoorde, S., & Fowler, C. J. (2005). Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: Evidence that VDM11 acts as an FAAH substrate. British Journal of Pharmacology, 145, 885–893.
Acknowledgments
The authors gratefully acknowledge the technical assistance of LeAnna DeLoache and Craig Roelke. These studies were supported by NIH grant DA09155 (CJH and WBC) and NIH GM31278 and the Robert A. Welch Foundation (JRF).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hillard, C.J., Shi, L., Tuniki, V. et al. Studies of Anandamide Accumulation Inhibitors in Cerebellar Granule Neurons: Comparison to Inhibition of Fatty Acid Amide Hydrolase. J Mol Neurosci 33, 18–24 (2007). https://doi.org/10.1007/s12031-007-0045-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-007-0045-0